SGLT2 Inhibitors Tied to Lower Kidney Cancer Risk - Takeaways - MDSpire

SGLT2 Inhibitors Tied to Lower Kidney Cancer Risk

A Korean cohort study found fewer kidney cancer cases among patients with type 2 diabetes who initiated sodium-glucose cotransporter 2 inhibitors vs dipeptidyl peptidase-4 inhibitors.

  • By

  • Andrea Surnit

  • June 9, 2026

  • 5 min

Share

  • 1

    SGLT2 inhibitors are associated with a lower incidence of kidney cancer compared to DPP-4 inhibitors in patients with type 2 diabetes.

  • 2

    The study involved 57,103 users of SGLT2 inhibitors and 57,103 users of DPP-4 inhibitors, with a follow-up of approximately 3.5 years.

  • 3

    SGLT2 inhibitor users had a 40% lower hazard of kidney cancer, with an incidence rate of 18.9 cases per 100,000 person-years.

  • 4

    The findings suggest potential mechanisms for reduced kidney cancer risk, but these were not directly tested in the study.

  • 5

    Limitations include observational design, short follow-up, and lack of individual agent data, affecting generalizability and potential confounding.

Original Source(s)

SGLT2 Inhibitors Tied to Lower Kidney Cancer Risk

  • by Andrea Surnit

  • June 9, 2026

Related Content

Vaginal DNA Assay Shows Promise

A two-marker methylated DNA assay identified endometrial cancer with 96% sensitivity in self-collected vaginal fluid — but prospective validation is needed before it can reduce biopsies in routine care.

MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors

Clinical study marks SurVaxM’s second phase 2 trial in a major cancer indication

  • May 7, 2026

  • 4 min
Postop Pain Differs by Vitamin D Status

Patients with preoperative vitamin D deficiency had higher postoperative pain scores and opioid use after mastectomy, including more than triple the odds of moderate to severe pain within 24 hours of surgery.